Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Front Med (Lausanne) ; 9: 894126, 2022.
Article in English | MEDLINE | ID: covidwho-2121050

ABSTRACT

Background and objectives: Although several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity. Methods: Patients admitted to 26 different hospitals located in 16 different provinces between March 11-July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation. Results: We retrospectively evaluated 1,472 COVID-19 adult patients; 57.1% were men (mean age = 51.9 ± 17.7years). A total of 210 (14.3%) had severe pneumonia, 115 (7.8%) were admitted to ICUs, and 69 (4.7%) were intubated during hospitalization. The median (interquartile range) of duration of hospitalization, including ICU admission, was 7 (5-12) days. Favipiravir (n = 328), lopinavir/ritonavir (n = 55), and oseltamivir (n = 761) were administered as antiviral agents, and hydroxychloroquine (HCQ, n = 1,382) and azithromycin (n = 738) were used for their immunomodulatory activity. Lopinavir/ritonavir (ß [95% CI]: 4.71 [2.31-7.11]; p = 0.001), favipiravir (ß [95% CI]: 3.55 [2.56-4.55]; p = 0.001) and HCQ (ß [95% CI]: 0.84 [0.02-1.67]; p = 0.046) were associated with increased risk of lengthy hospital stays. Furthermore, favipiravir was associated with increased risks of ICU admission (OR [95% CI]: 3.02 [1.70-5.35]; p = 0.001) and invasive mechanical ventilation requirement (OR [95% CI]: 2.94 [1.28-6.75]; p = 0.011). Conclusion: Our findings demonstrated that antiviral drugs including lopinavir, ritonavir, and favipiravir were associated with negative clinical outcomes such as increased risks for lengthy hospital stay, ICU admission, and invasive mechanical ventilation requirement. Therefore, repurposing such agents without proven clinical evidence might not be the best approach for COVID-19 treatment.

2.
Frontiers in medicine ; 9, 2022.
Article in English | EuropePMC | ID: covidwho-2033752

ABSTRACT

Background and objectives Although several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity. Methods Patients admitted to 26 different hospitals located in 16 different provinces between March 11–July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation. Results We retrospectively evaluated 1,472 COVID-19 adult patients;57.1% were men (mean age = 51.9 ± 17.7years). A total of 210 (14.3%) had severe pneumonia, 115 (7.8%) were admitted to ICUs, and 69 (4.7%) were intubated during hospitalization. The median (interquartile range) of duration of hospitalization, including ICU admission, was 7 (5–12) days. Favipiravir (n = 328), lopinavir/ritonavir (n = 55), and oseltamivir (n = 761) were administered as antiviral agents, and hydroxychloroquine (HCQ, n = 1,382) and azithromycin (n = 738) were used for their immunomodulatory activity. Lopinavir/ritonavir (β [95% CI]: 4.71 [2.31–7.11];p = 0.001), favipiravir (β [95% CI]: 3.55 [2.56–4.55];p = 0.001) and HCQ (β [95% CI]: 0.84 [0.02–1.67];p = 0.046) were associated with increased risk of lengthy hospital stays. Furthermore, favipiravir was associated with increased risks of ICU admission (OR [95% CI]: 3.02 [1.70–5.35];p = 0.001) and invasive mechanical ventilation requirement (OR [95% CI]: 2.94 [1.28–6.75];p = 0.011). Conclusion Our findings demonstrated that antiviral drugs including lopinavir, ritonavir, and favipiravir were associated with negative clinical outcomes such as increased risks for lengthy hospital stay, ICU admission, and invasive mechanical ventilation requirement. Therefore, repurposing such agents without proven clinical evidence might not be the best approach for COVID-19 treatment.

3.
Turk Thorac J ; 23(4): 296-301, 2022 07.
Article in English | MEDLINE | ID: covidwho-1997969

ABSTRACT

Tobacco addiction, which causes the death of more than 8.5 million people in the world every year, is a preventable global public health problem. There are 1.1 billion adult smokers worldwide and 60% of them desire or intend to quit but unfortunately, the tobacco industry continues to profit at the expense of people's lives by marketing electronic cigarettes and heated tobacco products as a smoking cessation method and they continue to poison young people with new threat tobacco products, promising a "smoke-free future" Turkish Thoracic Society is actively involved in the implementation of the National Tobacco Control Program to protect public health and has warned and raised awareness of new threats to the youth, such as electronic cigarettes and heated tobacco products. The purpose of this report is to provide information about electronic cigarettes and heated tobacco products and to present TTJ's position on the subject.

4.
Turk Thorac J ; 23(3): 225-230, 2022 May.
Article in English | MEDLINE | ID: covidwho-1847550

ABSTRACT

OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19) demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical outcomes. As an interleukin-6 receptor antagonist, tocilizumab is a promising treatment option for COVID-19. This study aimed to evaluate the clinical predictors of mortality for critically ill COVID-19 patients receiving tocilizumab therapy. MATERIAL AND METHODS: The retrospective cohort study was conducted in 4 centers' both wards and intensive care units between March 20 and May 20, 2020. Demographic, clinical, and laboratory data were consecutively drawn from medical records. The primary endpoint was in-hospital mortality. RESULTS: In this study, 39 patients (28.2% female) were included, and the mortality rate was 25.6% (n = 10). There was statistically significant difference between survivor and non-survivor groups regarding age (53.0 (46.5-65.0) vs. 75.0 (68.25-81.25), respectively,P = .001), CALL score (8.0 (7.0-10.0) vs. 12.0 (9.75-13.0), P = .001), GRAM score (119.5 (99.5-142.0) vs. 155.0 (129.8-226.0), P = .004), and white blood cell count (k/mL) (5.6 (3.8-8.6) vs. 8.0 (7.6-9.3), P = .003). The patients who were on invasive mechanical ventilation at the time of tocilizumab administration had a higher mortality rate (100% vs. 25.9%, P < .001). Besides, arterial partial pressure of oxygen/ fraction of inspiratory oxygen (PaO2/FiO2) ratio on day 7, but not on days 0, 1, and 3 of tocilizumab therapy, was associated with mortal- ity. C-reactive protein (mg/dL) tended to be lower in the survivor group; however, it was not statistically significant (68.4 (32.7-157.5) vs. 113.5 (77.7-219.0), P = .058). CONCLUSION: This study demonstrated that advanced age, increased leukocyte count, higher CALL and GRAM scores, and the need for invasive mechanical ventilation revealed a worse prognosis after tocilizumab treatment.

5.
Turk Thorac J ; 23(1): 63-69, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1726537

ABSTRACT

OBJECTIVE: The COVID-19 pandemic has demonstrated that the social determinants of health play a fundamental role in the course of the pandemic. This article aims to reveal the class dynamics of the COVID-19 epidemic in Istanbul, Turkey. MATERIAL AND METHODS: Spatial analysis and geographic information system data provided by Istanbul Metropolitan Municipality for March and April 2020 were used. Public transport mobility and turnstile data were analyzed. The data obtained were collated into thematic maps. RESULTS: Between March 16 and 24, 2020, the use of public transportation declined with the tightening of movement restrictions. However, despite the restrictions, an increase in transportation density was observed between 6 and 9 am and between 5 and 7 pm. Although the overall mobility toward outside the city has fallen due to travel restrictions, it has been observed that exit mobility continued between Gebze and Kocaeli, both industrial centers where blue-collar jobs dominate. Most of the mobility in the city is observed in Avcilar, Bahçelievler, Esenyurt, and Küçükçekmece, which are mostly blue-collar residential districts. On the Asian side, activity was observed in Kurtköy, Pendik, Samandira, Ümraniye, and Tuzla, areas where blue-collar workers predominantly reside. From March 25 to April 7, 2020, it was determined that the most intense activity areas of the blue-collar workers were Avcilar, Bahçelievler, Bagcilar, Çekmeköy, Esenyurt, Küçükçekmece, Ümraniye, and D-100 highway line. CONCLUSION: The density in the use of public transportation rose during the hours corresponding to the working hours of the workers who had to continue working despite the pandemic. In addition, the physical movement of blue-collar workers continued despite the travel restrictions imposed along the city borders where they worked and resided. Our data point to the importance of social protection measures for workers in general, and blue-collar workers in particular, for the management of the pandemic.

6.
Turk Thorac J ; 21(3): 215-216, 2020 May.
Article in English | MEDLINE | ID: covidwho-1296101
7.
Respir Med ; 183: 106433, 2021 07.
Article in English | MEDLINE | ID: covidwho-1217611

ABSTRACT

The COVID-19-related death rate varies between countries and is affected by various risk factors. This multicenter registry study was designed to evaluate the mortality rate and the related risk factors in Turkey. We retrospectively evaluated 1500 adults with COVID-19 from 26 centers who were hospitalized between March 11 and July 31, 2020. In the study group, 1041 and 459 cases were diagnosed as definite and highly probable cases, respectively. There were 993 PCR-positive cases (66.2%). Among all cases, 1144 (76.3%) were diagnosed with non-severe pneumonia, whereas 212 (14.1%) had severe pneumonia. Death occurred in 67 patients, corresponding to a mortality rate of 4.5% (95% CI:3.5-5.6). The univariate analysis demonstrated that various factors, including male sex, age ≥65 years and the presence of dyspnea or confusion, malignity, chronic obstructive lung disease, interstitial lung disease, immunosuppressive conditions, severe pneumonia, multiorgan dysfunction, and sepsis, were positively associated with mortality. Favipiravir, hydroxychloroquine and azithromycin were not associated with survival. Following multivariate analysis, male sex, severe pneumonia, multiorgan dysfunction, malignancy, sepsis and interstitial lung diseases were found to be independent risk factors for mortality. Among the biomarkers, procalcitonin levels on the 3rd-5th days of admission showed the strongest associations with mortality (OR: 6.18; 1.6-23.93). This study demonstrated that the mortality rate in hospitalized patients in the early phase of the COVID-19 pandemic was a serious threat and that those patients with male sex, severe pneumonia, multiorgan dysfunction, malignancy, sepsis and interstitial lung diseases were at increased risk of mortality; therefore, such patients should be closely monitored.


Subject(s)
COVID-19/mortality , Pandemics , Population Surveillance , Aged , Female , Humans , Male , Middle Aged , Retrospective Studies , Risk Factors , Survival Rate/trends , Turkey/epidemiology
8.
Turkish Journal of Geriatrics-Turk Geriatri Dergisi ; 24(1):13-22, 2021.
Article in English | Web of Science | ID: covidwho-1200504

ABSTRACT

Introduction: This research investigates the effectiveness of measures taken against the COVID-19 pandemic in nursing homes under the responsibility of the Istanbul Metropolitan Municipality. Materials and Method: Documents, decisions, and statistical data from the Istanbul Hospice gathered between March 1 and May 31. Results: The average age of the nursing home residents was 70.2. Among them, 29.0% were capable of self-care, while 31.4% were fully dependent on others for care. Visitor restrictions, social function cancellations, fever and complaint follow-up, institutional disinfection, the use of personal protective equipment, placarding, new employee shifts, short stays and isolation areas, personnel services, employees and resident screening tests, cargo limitations, and psychologist-sociologist support were implemented in the home to help deal with the pandemic. In all, 14 of 930 employees tested positive for the virus when given a COVID-19 PCR test. A total of 104 bed-dependent residents received PCR screening tests, and none were positive for the virus. There were 23 deaths in total (3.3%). There were no definite COVID-19-related deaths. The probable case-related mortality rate was 0.5%. Conclusion: Our research shows that the measures taken to address the COVID-19 pandemic in the nursing homes run by the Istanbul Hospice were timely and effective. Our data indicates that, if the finance and service structures of the nursing homes are met, and local authorities have control over the administrative organization, there will be no fatal outbreaks associated with COVID-19.

9.
Turk Thorac J ; 21(6): 419-432, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-993997

ABSTRACT

It has been more than 3 months now since the first case of COVID-19 was reported in Turkey. Globally, the number of confirmed cases and deaths reached 9,653,048 and 491,128 respectively, as reported by 216 countries by June 27, 2020. Turkey had 1,396 new cases, 194,511 total cases, and 5,065 deaths by the same date. From the first case until today, the Turkish Thoracic Society (TTS) has been very proactive in educating doctors, increasing public awareness, undertaking academic studies, and assisting with public health policies. In the present report, social, academic, and management perspectives of the pandemic are presented under appropriate subtitles. During this critical public health crisis, TTS has once again demonstrated its readiness and constructive stance by supporting public health, healthcare workers, and the environment. This review summarizes the perspective of TTS on each aspect of the COVID-19 pandemic and casts light on its contributions.

10.
Turk Thorac J ; 21(6): 433-437, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-993992

ABSTRACT

The prison population is one of the high-risk groups for coronavirus disease 2019 (COVID-19) pandemic. Apart from being in disadvantageous settings of "social distancing," people in prisons are frequently elderly and with multiple comorbidities as a reflection of discriminatory punitive policies worldwide. Although the universal human rights principles ensure that prisoners, like everyone else, live their lives in a healthy environment and access qualified healthcare when they are sick, without being discriminated, the prison conditions make it difficult to comply with these principles. In this review, the basic principles and recommendations on this subject have been reviewed in the context of the COVID-19 outbreak. In addition, the situation in Turkey's prisons was reviewed immediately before the transition to a "controlled social life."

SELECTION OF CITATIONS
SEARCH DETAIL